In “The Techno-Feudal Trap,” the authors deliver a gut-punch of reality: eleven companies control nearly everything on those shelves. Not eleven hundred. Eleven. Nestlé, PepsiCo, Coca-Cola and a handful of others have mastered what’s called “brand proliferation.” They create dozens of labels that look like competitors—Froot Loops next to Cheerios—but both are owned by the same corporate monster. You’re not choosing between businesses. You’re choosing between different masks.
The book traces how this concentration of power wasn’t an accident. It was engineered. The Sherman Antitrust Act of 1890 was supposed to break up monopolies. For a time, it worked. Standard Oil was broken up into 34 companies. Then came the 1970s and a legal philosophy called the “consumer welfare standard” gutted enforcement. Suddenly, as long as a monopoly didn’t raise prices that day, regulators looked the other way. They ignored the crushed competitors, the stolen innovation, the corrupted politics.
The authors brilliantly explain how this created what they call “techno-feudalism.” In old feudalism, you were a serf tied to the land. In techno-feudalism, you’re a user tied to a platform. You pay tribute with your attention, your data, your money. Small businesses pay a 30% tax to app stores. Drivers pay commissions to Uber. Sellers pay fees to Amazon. The platform owners don’t produce value—they extract it. They’re the new lords and we’re the digital serfs.
The health-industrial complex: They profit when you suffer
The book pulls no punches: Big Pharma’s business model depends on you being sick, not getting well. A one-time cure is a financial disaster for companies that rely on repeat prescriptions.
The authors walk us through the mechanics of this corruption. “Disease mongering” turns normal human experiences into medical conditions. Fidgety legs become “Restless Leg Syndrome.” Shyness becomes “Social Anxiety Disorder.” Suddenly, millions of healthy people become lifetime customers.
Then there’s the “patent cliff” strategy. When a drug’s patent is about to expire, companies don’t create new medicines. They make tiny changes—switch from capsule to tablet, change the dosage—and get a fresh patent. Same drug, new monopoly, continued high prices.